{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:32:22Z","timestamp":1789619542060,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"10555","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/s0140-6736(26)01248-1","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:45:13Z","timestamp":1785451513000},"page":"621-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial"],"prefix":"10.1016","volume":"408","author":[{"given":"Pablo","family":"Mora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita R","family":"Aroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisse","family":"Asong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bl\u00fcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Dam","family":"Heftdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda-Louise Fenger","family":"Carlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Nygaard","family":"Vilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(26)01248-1_bib1","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(26)01248-1_bib2","first-page":"S166","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(26)01248-1_bib3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/dom.12971","article-title":"Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes","volume":"19","author":"Gummesson","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S0140-6736(26)01248-1_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01248-1_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(26)01248-1_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01248-1_bib7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01248-1_bib8","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01248-1_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01248-1_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031517","article-title":"Amylin, another important neuroendocrine hormone for the treatment of diabesity","volume":"25","author":"Er\u017een","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/S0140-6736(26)01248-1_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s42255-026-01465-4","article-title":"The story of amylin: from physiology to therapy","volume":"8","author":"Secher","year":"2026","journal-title":"Nat Metab"},{"key":"10.1016\/S0140-6736(26)01248-1_bib13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(26)01248-1_bib14","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01248-1_bib15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01248-1_bib16","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01248-1_bib17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-8587(26)00125-7","article-title":"Cagrilintide\u2013semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study","volume":"14","author":"Buse","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(26)01248-1_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(26)01022-6","article-title":"Cagrilintide\u2013semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"408","author":"Rosenstock","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01248-1_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105862","article-title":"The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats","volume":"118","author":"Kuhre","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/S0140-6736(26)01248-1_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01248-1_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01248-1_bib24","article-title":"Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial","author":"Mora","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01248-1_bib25","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01248-1_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01248-1_bib27","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01248-1_bib28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01248-1_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(26)01248-1_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jamainternmed.2025.8222","article-title":"Heterogeneity of treatment effects of glucagon-like peptide-1 receptor agonists for weight loss in adults: a systematic review and meta-analysis","volume":"186","author":"Alexander","year":"2026","journal-title":"JAMA Intern Med"},{"key":"10.1016\/S0140-6736(26)01248-1_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"key":"10.1016\/S0140-6736(26)01248-1_bib32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673626012481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673626012481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T19:25:28Z","timestamp":1787513128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673626012481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"10555","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0140673626012481"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(26)01248-1","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(26)01248-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(26)01487-X","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}